Biocon Ltd, in collaboration with its European partner Zentiva, has obtained decentralised procedure approval in the European Union for their complex formulation, Liraglutide, which is used to manage diabetes and support weight management.
The approval covers generic versions of Victoza, indicated for treating Type-2 Diabetes, and Saxenda, used for weight management, Biocon Ltd stated in a regulatory filing.
Victoza and Saxenda are trademarks owned by Novo Nordisk.
Apple CEO Tim Cook announced on Friday that the company achieved record quarterly sales in India during the October-December period, with the iPhone emerging as the best-selling smartphone model in the country....
Reliance Consumer Products Ltd (RCPL) has joined forces with legendary Sri Lankan cricketer Muttiah Muralitharan to develop, manufacture, and market a new sports drink brand in India called Spinner. This collaboration aims...
The Railways is operating 360 trains, including 190 special trains, to accommodate the millions of devotees expected to attend the Maha Kumbh Mela on 'Mauni Amavasya', Chairman and CEO of the Railway...
Disney+ Hotstar’s live stream of Coldplay’s Music of the Spheres World Tour concert in Ahmedabad attracted an impressive 83 lakh views and accumulated 16.5 crore minutes of watch time. The event witnessed...
The Industry Insights Magazine is a monthly tech/review magazine with a twist, addressing all your Tech Woes. Be it news, views or reviews, we strive together to deliver the best content related to industry and technology
Discussion about this post